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Background: In many tumors including ovarian cancer, cell proliferation and apoptosis are important in
pathogenesis and there are many alterations in most of the genes related to the cell cycle. This study was designed
to evaluate immunohistochemistry with apoptotic-antiapoptotic proteins (p53, p21, bax, and bcl-2), c-kit,
telomerase, and metallothionein as a diagnostic aid in typing of benign, borderline, and malignant serous and
mucinous ovarian tumors.
Methods: Total of 68 ovarian tumors, 25 benign [13 (19.1%) serous and12 (17.6%) mucinous], 16 borderline [9
(13.2%) serous and 7(10.3%) mucinous], and 27 malignant ovarian tumors [24 (35.3%) serous and 3 (4.4%) mucinous
tumors] were included in the study. Immunohistochemical expression of p53, p21, bax, bcl–2, telomerase, c-kit, and
metallothionein were evaluated.
Results: When all 68 cases were evaluated as benign, borderline, and malignant ovarian tumors without
considering histopathological subtypes, the p53, p21, bax and metallothionein showed significantly higher staining
scores in the borderline and malignant ones (p < 0.05). After evaluation of all 68 cases, the serous tumors showed
significantly higher staining scores of p53, p21, c-kit, and metallothionein compared to the mucinous ones
(p < 0.05). For differentiation of benign and borderline and malignant tumors combined, p53 was not used because
all benign tumors has no staining, and p21, bax, and metallothionein was determined the significant predictors for
borderline and malignant tumors combined (p < 0.05). For differentiation of borderline and malignant tumors, only
p53 was determined the significant predictor for malignant tumors (p < 0.05).
Conclusions: In conclusion, p53, p21, bax, c-kit, and metallothionein may be helpful for the typing of ovarian
tumors as benign, borderline and malignant or serous and mucinous. p53, p21, bax, c-kit, and metallothionein may
have different roles in the pathogenesis of ovarian tumor types. p53 and metallothionein may be helpful in the
typing of borderline and malignant ovarian tumors. The immunohistochemical staining with bcl-2 and telomerase
may not provide meaningful contribution for the typing of ovarian tumors.
Virtual slide: The virtual slides for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/
2013030833768498
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Although outcome has improved significantly for many
solid cancers, survival of women with epithelial ovarian
cancer has changed little since platinum-based treatment
was introduced over 30 years ago [1-3]. Invasive epithe-
lial ovarian cancer is widely viewed and treated as a sin-
gle disease entity with little stratification of histological
or molecular subtypes. More than 70% of cases are
diagnosed with advanced disease because of the lack of
specific symptoms in early stage. Survival rates for early-
stage disease are greater than 90%; however, in advanced
stage, survival is less than 30%. Although the prognosis
of ovarian cancer is based on clinicopathological para-
meters, these features have been accepted insufficient to
define and predict response to chemotherapy. Thus to
predict outcome of the patients, new prognostic para-
meters have been investigated [4,5].
In the typing of ovarian tumors, the concept of bor-
derline ovarian tumor, known as low malignant potential
tumors, is the most controversial issue in gynecological
pathology because of lack of consensus about the histo-
logical criteria for borderline tumors. This increases in
need to develop panels of immunohistochemical staining
with increased specificity to ovarian tumor types [6-12].
Data of several studies related to immunohistochemis-
try in ovarian tumors support that tumor associated
markers can reliably predict the rate of progression and
the response to chemotherapy and can facilitate ovarian
cancer typing. Thus, several protooncogenes, tumor sup-
pressor genes, and apoptosis related genes including
bax, bcl-2, p53, p21, myc, ras, and HER-2/neu have been
investigated in ovarian tumors [6-8,10,13-19].
Apoptosis can be initiated by intracellular death sig-
nals that increase the level of p53, and also by extracel-
lular signals mediated by bax/bcl–2 complex. Although
apoptosis related protein expression has been reported
in ovarian epithelial cancer, there are few data in border-
line tumors [6,7,10].
The c-kit protooncogene encodes a tyrosine kinase re-
ceptor for stem cell factor that is expressed in various
tumors [20]. A previous study suggested that c-kit play
an important role in normal ovarian surface epithelium
and progression of ovarian cancer [21]; however, c-kit
protooncogene in ovarian cancer has rarely been
studied.
Telomeres are specific DNA–protein complexes,
located at the end of eukaryotic chromosomes and es-
sential for chromosome stability 19. Telomeres are pro-
gressively shortened with each cell division. Telomerase
maintains telomeres and by activation of this enzyme,
cells are able to overcome replicative senescence and to
divide indefinitely. Telomerase is frequently activated in
many kinds of cancers but not in most normal tissues
except germ cells of the ovary and testis. Thus, it hasbeen reported that telomerase activity is a useful tumor
marker for the diagnosis and prognosis of ovarian cancer
[11,12].
Metallothioneins are low molecular weight protein
involved in metalloregulatory function. In recent years,
metallothionein expression has been linked with car-
cinogenesis, resistance to cancer therapy and tumor
progression. In reported studies included ovarian carcin-
oma, expression of metallothionein have been observed.
Studies also have shown that metallothionein expres-
sion could be high in high-grade ovarian carcinomas
and they might play a role in the differential diagnosis
of the borderline and malignant ovarian carcinomas
[15,16,22,23].
The aim of this study was to evaluate immunohisto-
chemistry with apoptotic-antiapoptotic proteins (p53,
p21, bax, and bcl-2), c-kit, telomerase, and metallothio-
nein as a diagnostic aid in typing of benign, borderline,
and malignant serous and mucinous ovarian tumors.
Materials and methods
Patients
In the present study, tissue samples were obtained from
patients who underwent primary surgery for ovarian
tumors between 1999 and 2009 in the Gynecology Ser-
vice of Cumhuriyet University Hospital. Sixty eight ovar-
ian tumor specimens were included the study. The
samples consisted of 25 benign (13 serous and 12 mu-
cinous), 16 borderline (9 serous and 7 mucinous), and
27 malignant ovarian tumors (24 serous and 3 mucin-
ous). Accordance of histopathological diagnosis and
findings collected during clinical follow-up was evalu-
ated by reviewing patients’ charts before categorizing
cases to tumor types.
The histological type was confirmed by reviewing
hematoxylin/eosin stained slides. Tumor grading was
done according to the scoring system recommended by
Shimuzu et al. [24]. Due to that scoring system, nuclear
atypia (mild = 1, moderate = 2, severe = 3), mitotic activity
(0-9 = 1, 10-24 = 2, more than 25 = 3), and architecture
(glanduler = 1, papiller = 2, solid = 3) were described and
total score was counted as follows: score 3-5 = grade 1,
score 6-7 = grade 2, score 8-9 = grade 3.
Borderline and malignant tumors were staged accord-
ing to FIGO recommendations. Patient’s age, tumor
diameter, stage, and clinical findings were obtained from
pathology reports. One block per case representative for
the tumor was selected for immunohistochemistry.
Immunohistochemistry
Sections were deparaffinized in xylene and dehydrated
through graded concentrations of ethanol. After block-
ing of endogenous peroxidase activity with 3% hydrogen
peroxide for 15 minutes, the sections were heated in
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for 20 min. The slides were allowed to cool to room
temperature, and non- specific binding was blocked with
normal horse serum for 20 min at room temperature.
The sections were further incubated with the primary
antibody against p53 (Rabbit monoclonal, Clone SP5,
Neomarkers, USA), p21 (Mouse monoclonal, clone
HZ52 Neomarkers, USA), bax ( Mouse monoclonal,
Clone 2D2, Neomarkers, USA), bcl-2 ( Mouse monoclo-
nal Clone 8C8, Neomarkers, USA), c-kit (Mouse mono-
clonal Clone T595, Novacastro, UK), telomerase (Rabbit
polyclonal, Thermo scientific, USA), and metallothionein
(Mouse monoclonal, CloneE9, Neomarkers, USA) were
applied for 30 minutes. The sections were then stained
using avidin-biotin complex (ABC) by immunoperoxi-
dase technique employing commercially available re-
agent (ABC kit, Labvision, USA), for demonstration of
binding sites, ABC chromogen was applied. Phosphate
buffered saline was used for rinsing between each step
and finally all sections were counterstained with Mayer’s
hematoxylin.
Evaluation of immunostaining
Nuclear staining was considered as positive for p53, p21,
and telomerase. If more than 1% cells stained positive
for p53, p21, and telomerase, they were interpreted as
positive. The intensity of the staining was scored as fol-
lows: (+), (++), (+++), (++++) scores were accepted
when 1%-10%, 11%-25%, 25%-50%, and more than 50%
cells showed positive staining, respectively. CytoplasmicTable 1 Clinical and histopathological features of the cases
Benign (n= 25)
Serous Mucinous S
(n =13) (n = 12) (n
Laterality
Right 7 5 4
Left 5 5 2
Bilateral 1 2 3
Tumor size
<10 cm 7 3 3









IV -staining was interpreted as positive for bcl-2. Membran-
ous and cytoplasmic staining was considered positive for
bax and c-kit. Cytoplasmic and/or membranous staining
was considered positive for metallothionein. Quick score
was used for immunohistochemical evaluation of bcl-2,
bax, c-kit, and metallothionein [14]. According to this
score, intensity and percentage of positive staining of
cells were evaluated. Intensity of the staining was scored
as follows; 0 (no staining), 1 (weak), 2 (moderate), and 3
(strong). Percentage of the positive cells were scored as
0 (no staining), 1 (10 <%), 2 (10-50%), 3 (51-80%), and 4
(80%>). For each case, the values of the two parameters
(percentage of the positive cells and predominant inten-
sity) were multiplied, resulting in possible scores from 0
to 12 to obtain Ouick score.
Statistical analysis
Data were presented as median (min-max). Kruskal-
Wallis ANOVA was used for statistical analyses of stain-
ing scores according to histological types of ovarian
tumors. For immunohistochemical markers, logistic re-
gression analyses were performed to determine signifi-
cant predictors of malignant tumors. A p value of less
than 0.05 was accepted as significant.
Results
The age of the patients ranged from 19 to 82 years
(mean ± SD: 49.9 ± 16.2). Table 1 shows the clinical and
histopathological features of the 68 cases with ovarian
tumors. Overall, there was increased bilaterality in theBorderline (n = 16) Malignant (n = 27)
erous Mucinous Serous Mucinous













Table 3 Immunohistochemical staining scores of serous
and mucinous ovarian tumors
Serous (n = 47) Mucinous (n = 21) Significance
p53* 1 (0–4) 0 (0–4) p < 0.05
p21* 4 (0–4) 1 (0–4) P < 0.05
bax** 1 (0–6) 0 (0–4) NS
bcl-2 ** 0 (0–6) 0 (0–0) NS
c-kit ** 1 (0–12) 0 (0–4) p < 0.05
Telomerase* 0 (0–3) 0 (0–3) NS
Metallothionein** 6 (0–12) 1 (0–12) p < 0.05
NS, not significant. *Nuclear staining score. **Quick score.
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considerable large in the serous malignant ovarian
tumors, and the grade of tumor was higher in the serous
malignant ovarian tumors.
Table 2 presents the immunohistochemical staining
scores of p53, p21, bax, bcl–2, c-kit, telomerase, and
metallothionein in the benign, borderline, and malignant
ovarian tumors. When all 68 cases were evaluated as be-
nign, borderline, and malignant ovarian tumors without
considering histopathological subtypes, the p53, p21, bax
and metallothionein showed significantly higher staining
scores in the borderline and malignant tumors compared
to the benign ones (p < 0.05).
Table 3 shows the immunohistochemical staining
scores of p53, p21, bax, bcl–2, c-kit, telomerase, and
metallothionein in the serous and mucinous ovarian
tumors. After evaluation of all 68 cases, the serous
tumors showed significantly higher staining scores of
p53, p21, c-kit, and metallothionein compared to the
mucinous ones (p < 0.05) (Table 3).
Table 4 shows the immunohistochemical staining
scores of p53, p21, bax, bcl–2, c-kit, telomerase, and
metallothionein in the serous and mucinous ovarian
tumors as benign, borderline, and malignant. According
to the staining scores, the p53 staining score of border-
line and malignant serous tumors were significantly
higher than that of the benign serous tumors (p < 0.05).
There was no significant difference between the border-
line and malignant serous tumors with regard to the p53
staining score (p > 0.05). The p53 staining score of mu-
cinous cystadenocarcinoma was significantly higher than
that of the mucinous cystadenoma (p < 0.05), however,
we found no significant difference between borderline
and malignant mucinous tumor groups with regard to
the p53 staining score (p > 0.05). The p53 staining score
of borderline serous tumors were significantly higher
than that of the mucinous borderline tumors (p < 0.05).
There was no significant difference between serous
cystadenocarcinoma and mucinous cystadenocarcinomaTable 2 Immunohistochemical staining scores of benign,








p53 * 0 (0–0) 0.5 (0–3) 4 (0–4) p < 0.05
p21 * 1 (0–4) 3.5 (1–4) 4 (1–4) p = 0.05
bax ** 0 (0–2) 1 (0–4) 1 (0–6) p < 0.05
bcl-2 ** 0 (0–2) 0 (0–6) 0 (0–4) NS
c-kit ** 0 (0–6) 0 (0–4) 0 (0–12) NS
Telomerase* 0 (0–3) 0 (0–3) 0 (0–3) NS
Metallothionein** 0 (0–9) 3.5 (0–12) 6 (0–12) p < 0.05
Data were presented as median (min-max).
NS, not significant. *Nuclear staining score. **Quick score.with regard to the p53 staining score (p > 0.05)
(Figure 1a-c). In addition, the p53 staining score did not
differ between the benign serous and mucinous tumor
cases (p > 0.05).
We found significant differences among the benign,
borderline and malignant serous and mucinous ovarian
tumors with regard to the p21 staining score (p < 0.05).
With regard to the p21 staining, in serous tumors, there
were significant differences between the benign and bor-
derline and benign and malignant histological types
(p < 0.05). The p21 staining scores of borderline and ma-
lignant serous tumors were significantly higher than that
of the benign serous tumors (p < 0.05). The difference
was not significant between the borderline and malig-
nant serous tumors with regard to the p21 staining score
(p > 0.05) (Figure 1d-e). Although the p21 staining score
was not different between the malignant serous and mu-
cinous tumors (Figure 1f ), the benign and borderline
serous tumors showed higher p21 staining scores than
those of the mucinous counterparts (p < 0.05).
The bax staining score was significantly higher in the
borderline and malignant serous tumors compared to
the benign mucinous tumors (p < 0.05) (Figure 1g-i). Sig-
nificant differences were not found between serous and
mucinous tumors with regard to the bax staining score
(p > 0.05). In both of the serous and mucinous tumors,
the Bcl-2 staining score did not differ among the benign,
borderline, and malignant histological types (Figure 1k-
m) (p > 0.05) There was no significant difference be-
tween the serous and mucinous tumors with regard to
the Bcl-2 staining score (p > 0.05). Regarding to the c-kit
staining score, we found no significant difference among
the benign, borderline, and malignant tumors (Figure 2)
(p > 0.05). The serous tumors showed significantly higher
c-kit staining score compared to the mucinous tumors
(p < 0.05). Although the telomerase staining score in bor-
derline and malignant serous and mucinous tumors
showed higher values than benign tumors, the difference
did not reached statistical significance (p > 0.05)
(Figure 3).
Table 4 Immunohistochemical staining scores of serous and mucinous ovarian tumors as benign, borderline, and
malignant
Serous Mucinous
Benign Borderline Malignant Benign Borderline Malignant
(n = 13) (n = 9) (n = 24) (n = 12) (n =7) (n = 3)
p53* 0a 0 (0–1)b 4 (0–4)b 0 0 1 (0–4)c
p21* 3 (0–4)d,e 4 (1–4)f 4 (1–4)f 0.5 (0–4) 2 (1–4) 2 (2–4)
bax** 0 (0–2) 1 (0–4) 1 (0–6) 0 (0–1)g 0 (0–4) 1 (0–3)
bcl-2** 0 (0–2) 0 (0–4) 0 (0–4) 0 0 0
c-kit** 1 (0–6) 0 (0–4) 0.5 (0–12) 0 (0–4) 0 (0–1) 0
Telomerase* 0 (0–3) 0 (0–2) 0 (0–2) 0 0 (0–3) 1 (0–3)
Metallothionein** 2 (0–6) 4 (1–6)i 6 (0–12)i 0 (0–9) 2 (0–12)j 2 (1–6)
Data were presented as median (min-max). * Nuclear staining score. ** Quick score.
a,e,gP < 0.05 vs. borderline and malignant serous.
b,fP < 0.05 vs. benign and borderline mucinous.
c,iP < 0.05 vs. benign serous and benign mucinous.
d, jP < 0.05 vs. benign mucinous.
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were significant differences between the benign and bor-
derline serous tumors and between the benign and ma-
lignant serous tumors (p < 0.05). The borderline andFigure 1 Representative pictures of p53staining in a grade 2 serous c
carcinoma (c); p21 staining in a serous carcinoma (d), serous ovarian
a serous carcinoma (g), mucinous ovarian borderline tumor (h), and m
and serous ovarian borderline tumor (m). P53 and p21 immunostaining
outer of the membrane and the cytoplasm. Bcl-2 immunostaining was detmalignant tumors showed higher metallothionein stain-
ing score compared to the benign tumors. The differ-
ence in the metallothionein staining score was not
significant between borderline and malignant serousarcinoma (a), grade 1 serous carcinoma (b) and mucinous
borderline tumor (e), and mucinous carcinoma (f); bax staining in
ucinous carcinoma (i); bcl-2 staining in a serous carcinoma (k)
was restricted to the nuclei. Baxlabelling was observed in both the
ected in the cytoplasm. ([a-h, k-m] IHC; X100 and [i] IHC; X200).
Figure 2 Membranous and cytoplasmic staining for c-kit was
depicted in a serous carcinoma (IHC; X100).
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higher values in the borderline mucinous tumors com-
pared to the benign mucinous tumors (p < 0.05)
(Figure 4).
Table 5 includes odds ratios of immunohistochemical
marker to be determined as significant predictors of bor-
derline and malignant tumors. For differentiation of be-
nign and borderline and malignant tumors combined,
p53 was not used because all benign tumors has no
staining, and p21, bax, and metallothionein was deter-
mined the significant predictors for borderline and ma-
lignant tumors combined (p < 0.05). For differentiation
of borderline and malignant tumors, only p53 was deter-
mined the significant predictor for malignant tumors
(p < 0.05).
No significant associations were found between tumor
grades and immunohistochemical staining scores except
for p53 staining score (p > 0.05). The p53 staining posi-
tivity in the grade 2 and 3 cases were significantly higher
than that of the grade 1 cases (p < 0.05). However, there
was no significant difference between the grade 2 and 3
cases with regard to the p53 staining positivity (p > 0.05).
There were no significant association between the stageFigure 3 Telomerase nuclear staining in a serous carcinoma (a) and mof borderline and malignant ovarian tumors and all of
the immunohistochemical staining scores (p > 0.05).
Discussion
At present typing of ovarian tumors is of limited thera-
peutic significance because of management more
dependent on stage and grade of tumor, however, new
era of targeted therapy according to histological type of
ovarian cancer to reduce chemoresistance is in the be-
ginning. Reproducibility of typing of epithelial ovarian
cancer as borderline or malignant has significant inter-
observer variability for especially poorly differentiated
tumors. There is a need to develop panels of immuno-
histochemical staining markers suitable to rule out histo-
pathological types of ovarian tumors. Data of studies
investigating the reliability of several immonohistochem-
ical markers to differentiate ovarian tumors can lead to
development of diagnostic panels successful to confirm
histological type.
Tumor suppressor genes, protooncogenes, and
apoptosis-related genes have been implicated in the
regulation of ovarian carcinoma. Serous tumors and
some mucinous tumors may show BRAF and K-RAS
mutations [6-8,14,25-32]. The tumor suppressor gene
p53 is involved in the control of cell proliferation, par-
ticularly in stressed cells. p 53 gene mutations are the
most frequent genetic event found in various types of
cancers [33,34], and is the most common studied tumor
suppressor gene in ovarian carcinomas. High-grade ser-
ous tumors tended to be p53 positive and p53 positivity
is related to the survival rate. Although p53 is important
pathway for serous cystadenocarcinoma, prognostic
value of p53 is still controversial. Despite some studies
have clear evidence that p53 positivity is related with
grade, stage, and survival rate, some of the studies have
not found any relationship [17,18,35,36]. This apparent
discrepancy for p53 in ovarian carcinoma can be
explained by the heterogeneity of the tumors, differences
in immunohistochemistry methods and examination of
limited tumor cases in the studies. Fauvet et al. [7] have
found significant difference in p53 expression betweenucinous carcinoma (b). (IHC; X200).
Figure 4 Representative pictures of metallothionein staining in a serous carcinoma (a), serous ovarian borderline tumor (b), mucinous
ovarian borderline tumor (c), and mucinous carcinoma (d). Metallothionein staining was detected in the cytoplasm and/or membrane. ([a-d]
IHC; X100).
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cant difference was not found between borderline and
malignant tumors. Furthermore, they have not found
any differences in p53 expression of serous and mucin-
ous tumors. In our study, we found higher p53 staining
in borderline and malignant tumors compared to the be-
nign ones. However, we found comparable level of p53
staining between borderline and malignant tumors. In
addition, serous tumors showed higher p53 staining than
mucinous ones. Thus, our results support that especially






For differentiation of borderline and malignant tumorsa
p53* 2.1 1.2-3.8 p < 0.05
For differentiation of benign and borderline and malignant tumors
combinedb
p21* 1.7 1.0-2.8 P < 0.05
bax** 2.0 1.0-3.9 P < 0.05
Metallothionein** 1.5 1.1-1.9 p < 0.05
*Nuclear staining score. **Quick score.
aOnly p53 was determined the significant predictor for malignant tumors
during differentiation between borderline and malignant tumors.
bp21, bax, and metallothionein was determined the significant predictors for
borderline and malignant tumors combined during differentiation between
benign and borderline and malignant tumors combined.the typing of ovarian tumors, and it might be helpful in
differentiating benign and borderline ovarian tumors.
For differentiation of borderline and malignant tumors,
p53 may be used as a predictor for malignant tumors
(p < 0.05).
P21, a p53 inducible gene, encodes an inhibitor of cyc-
lin dependent kinases involved in G1 arrest. Studies
about p21 expression in ovarian carcinoma are contro-
versial [10,29,36]. Quellet et al. [29] have studied p21 ex-
pression in benign, borderline, and malignant ovarian
serous tumors. In this study in serous tumors, they have
found lower p21 expression than benign and borderline
tumors. According to this result, they thought that lower
expression of p21 might be the sign of aggressive poten-
tial of the tumor or might be poor prognostic parameter
[29]. However, in another study, p21 expression was
found lower in benign tumors than borderline and ma-
lignant tumors [36]. Fauvet et al. [7] have reported that
borderline tumors have higher p21 expression than be-
nign tumors. In that study, they suggested that overex-
pression of p21 is specific for serous tumors. In our
study, we found higher p21 staining in borderline and
malignant serous tumors than benign serous ones.
According to the result of the study of Fauvet et al. [7],
in our study, p21 staining in serous tumors was higher
than mucinous tumors. Our data involving both p21 and
p53 expression in ovarian tumors were similar with that
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play different role in the development of serous ovarian
tumors.
A proapoptotic gene bax induction by p53 is necessary
to inhibit tumor growth, and that the contribution of
bax to p53-mediated apoptosis is cell type dependent
[7]. Fauvet et al. [7] have reported that there were not
statistically significant differences in bax expression in
benign, borderline, and malignant ovarian serous and
mucinous tumors. Schuyer et al. [10] have found that
low bax expression might be poor prognostic parameter.
Skirnisdöttir et al. [6] have found the lowest rate of posi-
tive bax staining in mucinous tumors. In a study, a cor-
relation between high bax levels and improved clinical
outcome was also found [37]. In our study, there was
higher bax positive staining in borderline and malignant
ovarian tumors compared to the benign ones.
Regulators of apoptosis may be cell specific and the
first antiapoptotic gene identified was bcl-2. In a
reported study, bcl-2 has showed higher expression in
benign and borderline tumors than malignant tumors
[38]. Fauvet et al. [7] have reported that borderline
tumors have higher bcl-2 expression than benign and
malignant tumors. In the same study, they have showed
that although there was not difference in mucinous
tumors, serous tumors have significant difference in bcl-
2 positive staining. Thus, they have suggested that bcl-2
could be specific for serous tumors and might be related
with ovarian serous tumor pathogenesis. In our study,
bcl-2 positive staining was not found in none of the mu-
cinous tumors. Although benign, borderline, and malig-
nant serous tumors showed positive bcl–2 staining, we
found no difference reaching statistical significance,
moreover, serous and mucinous tumors did not differ in
bcl–2 staining.
The c-kit proto-oncogene encodes a tyrosine kinase
receptor and is expressed in various normal and tumor
tissues. In a reported study, c-kit expression has been
found 4.5% in low-grade serous carcinoma and 29.7% in
high-grade carcinoma [39]. Parrott et al. [21] have
showed that in advanced ovarian tumors, c-kit expres-
sion was high and they have suggested the importance
of c-kit expression in the progression of ovarian carcin-
omas. In a reported study, it has been found that mucin-
ous tumors have higher c-kit expression than serous
tumors [8]. In addition, in another study, the loss of c-
kit expression was found to be a poor prognostic factor
and it was reported that c-kit might play role in early
stage of ovarian carcinogenesis [8,13,14]. In this study,
in accordance with those findings, the immunohisto-
chemical staining with c-kit was remarkable in the ser-
ous ovarian tumors compared to the mucinous ones.
Telomerase activity is involved in the maintenance of
telomere length and is thought to be required foroncogenesis. Including ovarian carcinoma, in most of
the tumors high levels of telomerase activity was
reported [12,14]. It was demonstrated that there was
strong telomerase activity in borderline and malignant
tumors, however, in few or none of the benign tumors
and normal ovaries [11,12,14,40,41]. In accordance with
the reported cases, we found somewhat higher telomer-
ase staining in borderline and malignant serous and mu-
cinous tumors although it was not reached statistical
significance.
Metallothioneins are involved in cell proliferation,
growth, and differentiation. The significance of metal-
lothionein expression in ovarian cancers is inadequately
documented. Mccluggage et al. [9] have found metal-
lothionein expression in 56% of malignant ovarian car-
cinoma and in 2% of benign tumors. Because of this
finding, they have suggested that metallothionein may
play role in ovarian tumorogenesis [9]. In reported stud-
ies, high expression of metallothionein was found in ma-
lignant ovarian serous and mucinous tumors compared
with the benign tumors. Thus, it was suggested that
metallothionein has importance in ovarian tumorogen-
esis and it could be used as a prognostic parameter
[15,16,27,42]. The result of previous studies and this in-
vestigation support that during the diagnosis of border-
line and malignant ovarian tumors in difficult cases,
metallothionein expression could be used.
In conclusion, the immunohistochemical staining
with p53, p21, bax, c-kit, and metallothionein may be
helpful for the typing of ovarian tumors as benign,
borderline and malignant or serous and mucinous.
p53, p21, bax, c-kit, and metallothionein may have dif-
ferent roles in the pathogenesis of ovarian tumor types.
p53 and metallothionein may be helpful in the typing
of borderline and malignant ovarian tumors. The
immunohistochemical staining with bcl-2 and telomer-
ase may not provide meaningful contribution for the
typing of ovarian tumors. Because of limitations of low
number of cases in histopathological subtypes of ovar-
ian tumors, the results of this study needs to be sup-
ported by further studies with addition of new tumor
markers to develop a panel suitable for use in routine
pathology laboratories.
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